Breast Surgery — MCQs

Breast Surgery Indian Medical PG Practice Questions and MCQs

Question 101: All of the following are contraindications for breast conserving surgery except?

A. Tumors more than 4cm in size
B. Multicentricity
C. Centrally located tumor
D. Prior neoadjuvant chemotherapy (Correct Answer)

Explanation: **Explanation:** Breast Conserving Surgery (BCS) aims to achieve oncological safety while maintaining cosmesis. The correct answer is **Prior neoadjuvant chemotherapy (NACT)** because it is an **indication**, not a contraindication. In fact, NACT is frequently used to downstage large tumors (T2/T3) to a size where BCS becomes feasible, converting a potential mastectomy into a breast-conserving procedure. **Analysis of Options:** * **Tumors >4cm (Option A):** Large tumor size relative to breast volume is a relative contraindication. If the tumor-to-breast ratio is high, removing the tumor with adequate margins (1-2mm) results in significant deformity, defeating the purpose of BCS. * **Multicentricity (Option B):** This refers to multiple tumors in different quadrants of the breast. This is an **absolute contraindication** because it is impossible to remove all foci through a single incision with good cosmetic results, and it carries a high risk of local recurrence. * **Centrally located tumor (Option C):** Traditionally, tumors involving the nipple-areola complex (NAC) were contraindications. While modern "extreme" oncoplasty allows for central BCS, for standard NEET-PG purposes, central location (requiring NAC excision) remains a relative contraindication. **High-Yield Clinical Pearls for NEET-PG:** * **Absolute Contraindications for BCS:** Multicentricity, pregnancy (if radiotherapy is required during pregnancy), prior chest wall radiation, and persistent positive margins after re-excision. * **Relative Contraindications:** Collagen vascular diseases (e.g., Scleroderma/SLE due to poor radiation tolerance) and large tumor-to-breast ratio. * **Mandatory Requirement:** BCS must *always* be followed by **Radiotherapy** to reduce local recurrence. If a patient cannot access or tolerate radiation, BCS should not be performed.

Question 102: Triple examination of a breast lump includes all of the following except?

A. Clinical examination
B. Excision biopsy (Correct Answer)
C. Fine Needle Aspiration Cytology (FNAC)
D. Mammography

Explanation: The **Triple Assessment** (or Triple Examination) is the gold standard protocol for evaluating a breast lump to ensure maximum diagnostic accuracy (approaching 99%). It consists of three components: Clinical, Radiological, and Pathological. ### 1. Why "Excision Biopsy" is the Correct Answer Triple assessment is designed as a **non-invasive or minimally invasive** diagnostic tool to avoid unnecessary surgery. **Excision biopsy** is a surgical procedure where the entire lump is removed; it is considered the "gold standard" for definitive diagnosis but is **not** part of the initial triple assessment. If the triple assessment is concordant (all three tests suggest the same diagnosis), the need for an excision biopsy is often bypassed. ### 2. Analysis of Other Options * **Clinical Examination (Option A):** This is the first step, involving a detailed history and physical examination (inspection and palpation) of the breast and axilla. * **Mammography (Option D):** This represents the **Radiological** component. In women >35 years, mammography is preferred; in women <35 years, Ultrasound (USG) is preferred due to dense breast tissue. * **FNAC (Option C):** This represents the **Pathological/Cytological** component. While Core Needle Biopsy (CNB) is now increasingly preferred over FNAC (as it provides tissue architecture and receptor status), both fall under the pathological arm of the triple assessment. ### 3. Clinical Pearls for NEET-PG * **Concordance:** If all three components of the triple assessment are benign, the negative predictive value is **>99%**. * **Sequence:** The standard sequence is Clinical → Imaging → Pathology. * **Age Cut-off:** For radiological assessment, use **USG for <35 years** and **Mammography for >35 years**. * **Core Needle Biopsy (CNB):** It is superior to FNAC because it can differentiate between *in-situ* and invasive carcinoma and allows for IHC (ER/PR/HER2neu) testing.

Question 103: All of the following structures are presented in the Medical Research Methodology (MRM) except?

A. Axillary vessels
B. Bell's nerve
C. Cephalic vein
D. Nipple (Correct Answer)

Explanation: **Explanation:** The question refers to **Modified Radical Mastectomy (MRM)**, the standard surgical procedure for operable breast cancer. The primary goal of MRM is the removal of the entire breast tissue (including the nipple-areola complex and the fascia of the pectoralis major) along with a formal Level I and II axillary lymph node dissection. **Why "Nipple" is the correct answer:** In a standard MRM (specifically the **Auchincloss** or **Patey** modifications), the **nipple-areola complex is always sacrificed** as part of the elliptical skin incision to ensure oncological safety. Therefore, it is not "preserved" or "present" in the surgical field at the end of the procedure. **Analysis of Incorrect Options:** * **Axillary Vessels:** These form the superior boundary of the axillary dissection. While the axillary vein is skeletonized to remove associated lymph nodes, the vessels themselves are preserved. * **Bell’s Nerve (Long Thoracic Nerve):** This nerve supplies the Serratus Anterior muscle. It must be identified and preserved during axillary clearance to prevent "winging of the scapula." * **Cephalic Vein:** This vein runs in the deltopectoral groove. It serves as an important anatomical landmark for the superior limit of the dissection and is preserved. **High-Yield Clinical Pearls for NEET-PG:** 1. **Auchincloss Modification:** Removes breast + Level I & II nodes; preserves Pectoralis major and minor. 2. **Patey Modification:** Removes Pectoralis minor to facilitate Level III node clearance. 3. **Nerves at risk during MRM:** * **Long Thoracic Nerve (Bell’s):** Injury leads to Winging of Scapula. * **Thoracodorsal Nerve:** Supplies Latissimus Dorsi; injury weakens adduction/internal rotation. * **Intercostobrachial Nerve:** Most commonly injured nerve; leads to numbness of the inner arm.

Question 104: What is the surgical treatment for periductal mastitis?

A. Hadfield's operation (Correct Answer)
B. Patey's mastectomy
C. Modified radical mastectomy
D. None of the above

Explanation: **Explanation:** **Periductal mastitis** (also known as Zuska’s disease or plasma cell mastitis) is a chronic inflammatory condition characterized by the inflammation and dilation of the subareolar lactiferous ducts. It is strongly associated with **smoking**. 1. **Why Option A is correct:** **Hadfield’s operation** (Total Subareolar Breast Duct Excision) is the definitive surgical treatment for recurrent periductal mastitis or chronic mammary fistulae. The procedure involves the complete excision of all the major lactiferous ducts. Since the pathology resides in the diseased ducts, removing the entire ductal system from the base of the nipple effectively prevents recurrence. 2. **Why other options are incorrect:** * **Patey’s Mastectomy:** This is a Modified Radical Mastectomy (MRM) that involves removing the breast tissue and axillary lymph nodes while preserving the Pectoralis major muscle but sacrificing the Pectoralis minor. It is indicated for **breast cancer**, not benign inflammatory conditions. * **Modified Radical Mastectomy (MRM):** This is the standard surgical treatment for **operable breast carcinoma**. It is far too invasive for a benign condition like periductal mastitis. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factor:** Smoking is the single most important etiological factor (causes squamous metaplasia of the duct lining). * **Clinical Presentation:** Often presents as a subareolar mass, nipple discharge (thick/creamy), or a periareolar abscess/fistula. * **Management:** Initial treatment involves antibiotics (covering anaerobes like *Bacteroides*) and abscess drainage. Surgery (Hadfield’s) is reserved for chronic or recurrent cases. * **Differential Diagnosis:** Must be distinguished from mammary duct ectasia (which typically affects older, post-menopausal women and is not necessarily linked to smoking).

Question 105: Ipsilateral supraclavicular lymph nodes are positive in a patient with Ca Breast. What is the clinical stage?

A. Stage II
B. Stage III B
C. Stage III C (Correct Answer)
D. Stage IV

Explanation: ### Explanation The clinical staging of breast cancer follows the **AJCC TNM Staging System (8th Edition)**. The presence of positive **ipsilateral supraclavicular lymph nodes** is classified as **N3c** nodal involvement. **1. Why Stage III C is Correct:** According to the TNM classification, any **N3** disease (which includes metastasis to ipsilateral infraclavicular, internal mammary, or supraclavicular nodes) automatically categorizes the patient into **Stage III C**, regardless of the tumor size (T), provided there is no distant metastasis (M0). Specifically: * **N3a:** Ipsilateral infraclavicular nodes. * **N3b:** Ipsilateral internal mammary nodes + axillary nodes. * **N3c:** Ipsilateral supraclavicular nodes. **2. Why Other Options are Incorrect:** * **Stage II:** This stage involves smaller tumors (T1-T2) with limited mobile axillary nodes (N0-N1). Supraclavicular involvement is too advanced for this category. * **Stage III B:** This stage is defined by **T4** status (tumor involving the chest wall or skin, including inflammatory breast cancer) with N0-N2 nodes. It does not include N3 nodal status. * **Stage IV:** This represents **distant metastasis (M1)**. While supraclavicular nodes were once considered M1 (in older classifications), they are now classified as **regional** nodes (N3c). Stage IV would require spread to the lungs, bones, liver, or contralateral supraclavicular nodes. **High-Yield Clinical Pearls for NEET-PG:** * **Regional vs. Distant:** Ipsilateral supraclavicular nodes = **N3c (Stage IIIC)**; Contralateral supraclavicular nodes = **M1 (Stage IV)**. * **Internal Mammary Nodes:** If detected clinically, they are N3b; if detected only by sentinel node biopsy (microscopic), they are N1b. * **Sentinel Lymph Node Biopsy (SLNB):** The investigation of choice for clinically N0 axilla. * **Isolated Tumor Cells (ITC):** Defined as clusters <0.2 mm or <200 cells; they are staged as pN0(i+).

Question 106: Which of the following is the most significant risk factor for developing breast cancer?

A. The presence of sclerosing adenosis
B. Nulliparity
C. Atypical lobular hyperplasia
D. Atypical ductal hyperplasia (Correct Answer)

Explanation: **Explanation:** The risk of developing invasive breast cancer is categorized based on the histological findings of a breast biopsy. This question tests the ability to differentiate between non-proliferative, proliferative without atypia, and proliferative with atypia lesions. **Why Atypical Ductal Hyperplasia (ADH) is correct:** ADH and Atypical Lobular Hyperplasia (ALH) are both "proliferative lesions with atypia." These carry the highest relative risk (RR) among the options provided, typically **4.0 to 5.0 times** the risk of the general population. Between the two, ADH is often clinically prioritized as it shares genetic and morphologic features with low-grade DCIS, representing a direct precursor in the neoplastic continuum. **Analysis of Incorrect Options:** * **A. Sclerosing Adenosis:** This is a "proliferative lesion without atypia." It carries a low risk, with a RR of approximately **1.5 to 2.0**. * **B. Nulliparity:** This is a reproductive risk factor. While significant, its RR is relatively low (approx. **1.2 to 1.7**) compared to biopsy-proven cellular atypia. * **C. Atypical Lobular Hyperplasia:** While ALH also carries a high RR (4.0–5.0), in standardized surgical exams, ADH is frequently cited as the most significant histological marker of future risk among these choices due to its closer association with subsequent ductal carcinoma. **NEET-PG High-Yield Pearls:** 1. **Highest Risk Factor Overall:** A positive **BRCA1/BRCA2** mutation (RR >10). 2. **RR 1.5–2.0 (No Atypia):** Sclerosing adenosis, intraductal papilloma, radial scar, and moderate/florid hyperplasia. 3. **RR 4.0–5.0 (With Atypia):** ADH and ALH. 4. **RR 8.0–10.0:** Lobular Carcinoma in Situ (LCIS) and Ductal Carcinoma in Situ (DCIS). 5. **Gail Model:** The most commonly used clinical tool to estimate individual breast cancer risk.

Question 107: Which of the following conditions, as seen on Fine Needle Aspiration Cytology (FNAC), is most likely to appear malignant in a breast aspirate?

A. Intraductal Carcinoma in situ (Correct Answer)
B. Fibroadenoma
C. Fibroadenosis
D. Simple cyst

Explanation: **Explanation:** The core challenge in breast cytology is distinguishing between high-grade benign lesions and low-grade malignant ones. **Intraductal Carcinoma in situ (DCIS)** is the correct answer because it represents a pre-invasive malignant proliferation of epithelial cells. On FNAC, DCIS often yields highly cellular aspirates with significant nuclear pleomorphism, prominent nucleoli, and necrosis (especially in the comedo subtype). These features mimic invasive carcinoma, making it the most "malignant-looking" entity among the choices. **Analysis of Options:** * **Fibroadenoma:** While it can be hypercellular, it typically shows a characteristic "biphasic" pattern: cohesive "staghorn" clusters of ductal cells and numerous background "naked" bipolar nuclei. These features are hallmarks of benignity. * **Fibroadenosis (Fibrocystic changes):** This is a benign condition. Aspirates show low cellularity, apocrine metaplasia, and fragments of fibrous stroma without significant cytologic atypia. * **Simple Cyst:** FNAC usually yields only clear or straw-colored fluid with a few degenerated epithelial cells or macrophages. It lacks the cellular density and atypia required to appear malignant. **NEET-PG High-Yield Pearls:** * **Triple Assessment:** The gold standard for breast lump diagnosis includes Clinical Examination, Imaging (Mammography/USG), and Pathology (FNAC/Biopsy). * **FNAC vs. Core Needle Biopsy (CNB):** FNAC cannot distinguish between DCIS and invasive carcinoma because it lacks architectural context (basement membrane integrity). CNB is now preferred for suspicious lesions. * **Cribriform Pattern:** Often associated with low-grade DCIS. * **Comedo Necrosis:** A high-grade feature of DCIS that strongly mimics invasive cancer on cytology.

Question 108: According to the TNM staging system, what stage is assigned to breast carcinoma with positive bilateral supraclavicular lymph nodes?

A. N3a
B. N3b
C. N3c
D. M1 (Correct Answer)

Explanation: **Explanation:** The correct answer is **M1**. In the AJCC TNM staging system for breast cancer, the classification of regional lymph nodes is strictly anatomical. **1. Why M1 is correct:** According to the TNM staging, **ipsilateral** (same side) supraclavicular lymph nodes are classified as **N3c** (Stage IIIC). However, any involvement of **contralateral** (opposite side) lymph nodes—including supraclavicular, internal mammary, or axillary nodes—is considered distant metastasis. Therefore, **bilateral** supraclavicular involvement implies that the contralateral side is affected, automatically upgrading the stage to **M1 (Stage IV)**. **2. Why other options are incorrect:** * **N3a:** Refers to metastasis in ipsilateral infraclavicular lymph node(s). * **N3b:** Refers to metastasis in ipsilateral internal mammary lymph node(s) in the presence of axillary node involvement. * **N3c:** Refers to metastasis in **ipsilateral** supraclavicular lymph node(s). While the question mentions supraclavicular nodes, the "bilateral" nature moves it out of the "N" category into the "M" category. **Clinical Pearls for NEET-PG:** * **Ipsilateral Supraclavicular Nodes:** These were once considered M1 but were reclassified to **N3c** because aggressive local treatment (Radiotherapy/Surgery) can still offer a chance at cure. * **Contralateral Nodes:** Always signify **M1** disease. * **Sentinel Lymph Node Biopsy (SLNB):** The gold standard for axillary staging in clinically N0 (node-negative) patients. * **Most common site of distant metastasis:** Bone (specifically the spine due to Batson’s plexus).

Question 109: Carcinoma breast stage 4b involves which of the following, except?

A. Nipple retraction (Correct Answer)
B. Skin ulcer over the swelling
C. Dermal edema
D. Satellite nodule

Explanation: In the TNM staging of breast cancer, **Stage T4** represents advanced local disease involving the chest wall or skin. The distinction between T4 categories is a high-yield topic for NEET-PG. **Explanation of the Correct Answer:** **A. Nipple retraction** is the correct answer because it does **not** signify T4 disease. It occurs due to the infiltration of the lactiferous ducts by the tumor, leading to fibrosis and shortening of the ducts. This can happen even in early-stage tumors (T1 or T2) and does not change the T-stage of the cancer. **Explanation of Incorrect Options (T4b Criteria):** According to the AJCC staging, **T4b** is defined as edema (including *peau d'orange*), ulceration of the skin of the breast, or satellite skin nodules confined to the same breast. * **B. Skin ulcer:** Direct invasion of the epidermis by the tumor signifies T4b. * **C. Dermal edema:** This presents clinically as *peau d'orange* due to the obstruction of dermal lymphatics. It is a hallmark of T4b (and inflammatory breast cancer if involving >1/3 of the breast). * **D. Satellite nodules:** These are separate tumor nests in the skin of the same breast, indicating advanced local spread (T4b). **High-Yield Clinical Pearls for NEET-PG:** * **T4a:** Extension to the chest wall (serratus anterior, ribs, or intercostal muscles). Note: Invasion of the pectoralis muscle alone is **not** T4. * **T4c:** Presence of both T4a and T4b features. * **T4d:** Inflammatory carcinoma (characterized by rapid onset of erythema and edema). * **Dimpling of skin:** Occurs due to involvement of **Cooper’s ligaments**; like nipple retraction, it does not necessarily imply T4 disease.

Question 110: Which of the following is NOT true about breast carcinoma?

A. Positive family history is a risk factor.
B. The median age of presentation is about 40 years.
C. It is more common in Muslims. (Correct Answer)
D. All of the above are true statements.

Explanation: **Explanation:** Breast carcinoma is the most common malignancy among women globally and in India. Understanding its epidemiology and risk factors is crucial for NEET-PG. **Why Option C is the correct answer (False statement):** Epidemiological studies in India consistently show that breast cancer is **less common in Muslim women** compared to Hindu, Christian, or Parsi communities. This is attributed to socio-cultural factors such as early marriage, early first childbirth, and longer durations of breastfeeding, all of which are protective factors that reduce lifetime exposure to estrogen. **Analysis of other options:** * **Option A (True):** A positive family history, especially in first-degree relatives, significantly increases risk. About 5-10% of cases are hereditary, often linked to **BRCA1 and BRCA2** mutations. * **Option B (True):** While the peak incidence in Western countries is post-menopausal (50-60 years), the **median age of presentation in India is significantly younger**, typically occurring in the 4th and 5th decades (around 40-50 years). **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Upper Outer Quadrant (60%). * **Most common histological type:** Invasive Ductal Carcinoma (NOS). * **Risk Factors:** Nulliparity, early menarche (<12 years), late menopause (>55 years), and obesity (post-menopausal). * **Triple Assessment:** Clinical examination, Imaging (Mammography/Ultrasound), and Pathology (Core Needle Biopsy - *Gold Standard*). * **Molecular Subtypes:** Luminal A (ER/PR positive) has the best prognosis; Triple Negative (Basal-like) has the worst.

Practice by Chapter

Breast Anatomy and Physiology

Practice Questions

Benign Breast Diseases

Practice Questions

Breast Cancer Screening

Practice Questions

Breast Cancer: Diagnosis and Staging

Practice Questions

Surgical Management of Breast Cancer

Practice Questions

Oncoplastic Breast Surgery

Practice Questions

Sentinel Lymph Node Biopsy

Practice Questions

Axillary Surgery

Practice Questions

Breast Reconstruction Techniques

Practice Questions

Male Breast Disorders

Practice Questions

Phyllodes Tumors

Practice Questions

Management of Ductal Carcinoma In Situ

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free